Cargando…
The Potential of Combination Therapies and Patient Stratification to Improve CCR2 Inhibition Therapeutics
Autores principales: | Duex, Jason E., Theodorescu, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788950/ https://www.ncbi.nlm.nih.gov/pubmed/35083442 http://dx.doi.org/10.33696/immunology.3.099 |
Ejemplares similares
-
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
por: Tu, Megan M., et al.
Publicado: (2020) -
Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021) -
AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2022) -
Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors
por: Santamaria, Silvia, et al.
Publicado: (2022) -
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)